PayerTalkCE Presents: Managing DR/DME for Underserved Populations

Learn About:

1. Pharmacologic treatment options for DR/DME
2. The importance of remote screening and treatment with anti-VEGF therapies
3. Medical and pharmacy benefit design strategies

Expert Faculty Presenters:

Jordan M. Graff, MD, FACS Surgeon & Partner, BDP Eye Center at American Vision Partners (AVP) Chair, Division of Ophthalmology, Creighton University Clinical Assistant Professor, University of Arizona, Phoenix Medical Executive Committee, AVP - Phoenix, AZ Click here for biography Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
While the choice of treatment for retinal diseases is largely based on the experience and preference of the treating retinal specialist and patient preferences, payers are key stakeholders in impacting treatment selection through formulary placement, step therapy, and site-of-care policies which can affect member access. Based on findings from the 2022-2023 ManagedCareEye.com initiatives, disease state baseline knowledge and awareness has improved, but payers continue to need additional education to apply health plan best practices to improve retinal disease management.

Educational Objectives
After completing this activity, the participant should be better able to:

• Characterize pharmacologic treatment options for DR/DME in terms of efficacy, safety, and dosing intervals
• Describe the importance of remote screening and treatment with anti-VEGF therapies featuring extended duration of effect in rural patients
• Examine medical and pharmacy benefit design strategies that facilitate appropriate evidence-based treatment for DR/DME

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: UAN JA0003680-9999-24-192-L01-P
Type of Activity: Knowledge-based

Continuing Nursing Education
Medical Education Resources designates this live activity for a maximum of 0.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.5 contact hours.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.